PL2196206T3 - Środek do łagodzenia problemów skórnych zawierający pochodną morfinanu lub jego farmakologicznie dopuszczalną kwasową sól addycyjną jako substancję czynną - Google Patents

Środek do łagodzenia problemów skórnych zawierający pochodną morfinanu lub jego farmakologicznie dopuszczalną kwasową sól addycyjną jako substancję czynną

Info

Publication number
PL2196206T3
PL2196206T3 PL08835121T PL08835121T PL2196206T3 PL 2196206 T3 PL2196206 T3 PL 2196206T3 PL 08835121 T PL08835121 T PL 08835121T PL 08835121 T PL08835121 T PL 08835121T PL 2196206 T3 PL2196206 T3 PL 2196206T3
Authority
PL
Poland
Prior art keywords
remedy
active ingredient
acid addition
addition salt
pharmacologically acceptable
Prior art date
Application number
PL08835121T
Other languages
English (en)
Inventor
Shinji Ona
Koichiro Takeshita
Naoki Ando
Masahiro Yamashita
Original Assignee
Toray Industries, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries, Inc. filed Critical Toray Industries, Inc.
Publication of PL2196206T3 publication Critical patent/PL2196206T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
PL08835121T 2007-10-05 2008-10-03 Środek do łagodzenia problemów skórnych zawierający pochodną morfinanu lub jego farmakologicznie dopuszczalną kwasową sól addycyjną jako substancję czynną PL2196206T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007262015 2007-10-05
PCT/JP2008/068092 WO2009044883A1 (ja) 2007-10-05 2008-10-03 モルヒナン誘導体またはその薬理学的に許容される酸付加塩を有効成分とする皮膚性状改善治療薬
EP08835121.8A EP2196206B8 (en) 2007-10-05 2008-10-03 Remedy for relieving skin troubles comprising morphinan derivative or pharmacologically acceptable acid addition salt thereof as the active ingredient

Publications (1)

Publication Number Publication Date
PL2196206T3 true PL2196206T3 (pl) 2020-02-28

Family

ID=40526303

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08835121T PL2196206T3 (pl) 2007-10-05 2008-10-03 Środek do łagodzenia problemów skórnych zawierający pochodną morfinanu lub jego farmakologicznie dopuszczalną kwasową sól addycyjną jako substancję czynną

Country Status (14)

Country Link
US (1) US20100222309A1 (pl)
EP (1) EP2196206B8 (pl)
JP (1) JP5613417B2 (pl)
KR (1) KR101173509B1 (pl)
CN (1) CN101848714B (pl)
AU (1) AU2008308005B2 (pl)
BR (1) BRPI0817804A8 (pl)
CA (1) CA2702032C (pl)
ES (1) ES2748274T3 (pl)
MX (1) MX2010003660A (pl)
PL (1) PL2196206T3 (pl)
RU (1) RU2440117C1 (pl)
TW (1) TWI453020B (pl)
WO (1) WO2009044883A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX362830B (es) * 2010-01-29 2019-02-14 Toray Industries Agente terapeutico o profilactico para enfermedades del tracto biliar.
WO2012054566A2 (en) * 2010-10-19 2012-04-26 Memorial Sloan-Kettering Cancer Center 6-amido derivatives of 4,5a-epoxymorphinans for treatment of pain
ES2586655T3 (es) 2011-01-31 2016-10-18 Toray Industries, Inc. (-)-17-(ciclopropilmetil)-3,14beta-dihidroxi-4,5alfa-epoxi-6beta-[N-metil-trans-3-(3-furil)acrilamido]morfinano para su utilización en el tratamiento o prevención de la caquexia por cáncer
EP2931725B1 (en) 2012-12-14 2017-02-15 Purdue Pharma LP Nitrogen containing morphinan derivatives and the use thereof
CA2896202A1 (en) 2012-12-28 2014-07-03 Purdue Pharma L.P. Substituted morphinans and the use thereof
WO2016176657A1 (en) 2015-04-30 2016-11-03 Memorial Sloan-Kettering Cancer Center Mitragynine analogs and uses thereof
CN105461727A (zh) * 2015-12-01 2016-04-06 吕涛 一种纳呋拉啡的精制方法
WO2018160500A1 (en) 2017-03-03 2018-09-07 Ring Inc. Solar-charging mounting bracket for audio/video recording and communication devices
HUE069820T2 (hu) 2018-03-08 2025-04-28 Victoria Link Ltd Nalfurafin alkalmazása demielinizációs betegségek kezelésére
TWI893157B (zh) * 2020-06-30 2025-08-11 日商東麗股份有限公司 具有嗎啡喃骨架之化合物或其藥理學上可容許之酸加成鹽的用途
CR20230576A (es) 2021-06-14 2024-04-05 Scorpion Therapeutics Inc Derivados de la urea que pueden ser utilizados para tratar el cáncer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923875A (en) * 1989-07-10 1990-05-08 Baker Cummins Pharmaceuticals, Inc. Method for treatment of mast cell-mediated dermatologic disorders
JP2521853B2 (ja) 1990-07-25 1996-08-07 タカラベルモント株式会社 化粧料
US6323212B1 (en) 1992-01-23 2001-11-27 Toray Industries, Inc. Morphinan derivative and its pharmaceutical applications
EP0661283B1 (en) 1993-07-19 1998-10-21 Toray Industries, Inc. Brain cell protective
EP0663401B1 (en) * 1993-07-23 2000-06-07 Toray Industries, Inc. Morphinan derivative and medicinal use
JPH07187990A (ja) 1993-12-24 1995-07-25 Toshiko Yamamoto 化粧料
ATE359076T1 (de) * 1996-11-25 2007-05-15 Toray Industries Mittel gegen juckreiz
US5834480A (en) * 1997-06-13 1998-11-10 Elkhoury; George F. Topical application of opioids for treatment of acne and sebaceous gland disorders
WO1999005146A1 (en) 1997-07-25 1999-02-04 Toray Industries, Inc. Hyponatremia remedies
JP4359711B2 (ja) 1997-09-02 2009-11-04 東レ株式会社 薬物依存症治療薬
JP2000053572A (ja) 1998-08-11 2000-02-22 Toray Ind Inc ＯＲＬ１（ｏｐｉｏｉｄ ｏｒｐｈａｎ）受容体拮抗薬
DE60039444D1 (de) 1999-08-24 2008-08-21 Toray Industries Heilmittel für neuropathischen schmerz und versuchstier-modelle des neuropathischen schmerzes
CA2442423C (en) 2001-03-30 2009-11-03 Toray Industries, Inc. Therapeutic drug for psychoneurotic disorders
EP1402899A4 (en) 2001-05-08 2009-03-11 Toray Industries MEANS FOR THE TREATMENT OF SEPSIS
JP2004107209A (ja) 2002-09-13 2004-04-08 Nippon Oruganon Kk 掻痒治療薬
RU2221545C1 (ru) * 2002-11-13 2004-01-20 Открытое Акционерное Общество "Фаберлик" Косметическое средство, улучшающее физиологическое состояние кожных покровов
JP4499034B2 (ja) * 2003-02-19 2010-07-07 久光製薬株式会社 Ｎ−アリール又はｎ−ヘテロアリールピペラジン誘導体及びそれを含有する医薬
JP2004352714A (ja) 2003-05-08 2004-12-16 Kyorin Pharmaceut Co Ltd 新規な４−（２−フロイル）アミノピペリジン誘導体
JP4381157B2 (ja) 2004-02-03 2009-12-09 久光製薬株式会社 ２，２−ジフェニル−１−エタノン誘導体及びそれを含有する医薬
ATE456373T1 (de) * 2004-11-29 2010-02-15 Unilever Nv Orale zusammensetzung zur verbesserung der hauteigenschaften
PT1870413E (pt) * 2005-03-10 2013-10-01 Toray Industries Agente antiprurítico para o pruridro provocado pela esclerose múltipla
WO2007053194A2 (en) * 2005-06-03 2007-05-10 The University Of Chicago Modulation of cell barrier dysfunction
RU2299724C1 (ru) * 2005-11-14 2007-05-27 Открытое Акционерное Общество "Фаберлик" Средство, улучшающее физиологическое состояние клеток кожи

Also Published As

Publication number Publication date
CA2702032A1 (en) 2009-04-09
AU2008308005A1 (en) 2009-04-09
TWI453020B (zh) 2014-09-21
MX2010003660A (es) 2010-08-10
ES2748274T3 (es) 2020-03-16
CN101848714B (zh) 2014-08-20
JPWO2009044883A1 (ja) 2011-02-10
BRPI0817804A8 (pt) 2017-04-18
EP2196206A4 (en) 2010-09-22
CA2702032C (en) 2013-04-02
WO2009044883A1 (ja) 2009-04-09
KR20100049683A (ko) 2010-05-12
EP2196206A1 (en) 2010-06-16
RU2440117C1 (ru) 2012-01-20
CN101848714A (zh) 2010-09-29
US20100222309A1 (en) 2010-09-02
EP2196206B8 (en) 2019-11-13
EP2196206B1 (en) 2019-07-17
TW200927116A (en) 2009-07-01
JP5613417B2 (ja) 2014-10-22
KR101173509B1 (ko) 2012-08-14
BRPI0817804A2 (pt) 2016-10-11
AU2008308005B2 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
EP2196206B8 (en) Remedy for relieving skin troubles comprising morphinan derivative or pharmacologically acceptable acid addition salt thereof as the active ingredient
TWI366460B (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
WO2009017837A3 (en) Sublingual fentanyl spray
ZA200807767B (en) Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
WO2011014588A3 (en) Dermal formulations of dp2 receptor antagonists
WO2007087431A3 (en) Sublingual fentanyl spray
EP2166837A4 (en) DRUG COMBINATION USEFUL FOR THE TREATMENT OF SKIN DISORDERS
IL190338A0 (en) Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
PL2453923T3 (pl) Niekowalencyjne dostarczanie aktywnych czynników przez barierę krew-mózg przy udziale peptydów
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
ZA200709999B (en) Fungicidal active ingredient combination
WO2011014825A3 (en) Antiangiogenic small molecules and methods of use
AP2008004614A0 (en) Dividable galencial form allowing modified releaseof the active ingredient
PT1874746E (pt) Derivados de 1-n-azacicloalquil-3-fenoxipropano úteis para a preparação de medicamentos psicotrópicos
HK1202448A1 (en) Topical formulation for administering a compound
IL196394A0 (en) Implantable sustained drug delivery device for releasing active agents to the osteomeatal complex
IL201418A0 (en) Therapeutic agent for glaucoma containing adenosine derivative as active ingredient
WO2009041663A1 (ja) 皮膚疾患の予防及び／または治療剤
ZA200709788B (en) Cannabinold active pharmaceutical ingredient for Improved dosage forms
EP2415764A4 (en) PROPHYLACTIC AND / OR THERAPEUTIC AGENT AGAINST ANEMIA WITH A TETRAHYDROCHINOLINE COMPOUND AS AN ACTIVE SUBSTANCE
ZA200804757B (en) Fungicidal active ingredient combination
EP2157089A4 (en) THERAPEUTIC USES OF IMIDAZOL-5-CARBOXYLIC ACID DERIVATIVES
TWI369988B (en) New pharmaceutically active compounds for the treatment of respiratory diseases
WO2009011420A1 (ja) ２型糖尿病の治療薬
ZA201005394B (en) 15,16-methylene-17-hydroxy-19-nor-21-carboxylic acid y-lactone derivative,use thereof,and medicament containing said derivative